Introduction
The traditional view of Parkinson's disease PD as a pure motor disorder has been challenged in recent years by observations that some motor deficits in PD could be at least partially due to proprioceptive disturbances. These insights have thus far been derived mainly from studies on upper limb control (Schneider et al., 1987; Klockgether et al., 1995; Demirci et al., 1997; Zia et al., 2000; Adamovich et al., 2001; Maschke et al., 2003; Byblow et al., 2003; Keijsers et al., 2005) . For this reason, the recent findings of Wright and colleagues, published recently in Experimental Neurology (Wright et al., 2010) , provide a unique opportunity to investigate whether abnormal kinaesthesia in PD extends to axial joints as well. Here, we will discuss how these new results of Wright and colleagues extend our current knowledge on how PD may influence kinaesthesia. We will also review the pathophysiology underlying such kinaesthetic changes, and discuss the evidence in support of a proprioceptive contribution to balance deficits seen in PD.
Kinaesthetic deficits in Parkinson's disease
While there is now clear evidence that sensori-motor and visuomotor integration are influenced by PD (see e.g. Bronstein et al., 1990; Waterston et al., 1993) , the effect of PD on kinaesthesia alone is far less clear. Kinaesthesia is commonly defined as the ability to detect joint motion or a change in position of a joint. While common views of kinaesthesia rely primarily on outputs from spindles or joint receptors, recent work has demonstrated that cutaneous receptors also play a significant role in signalling changes in joint motion and position (Proske and Gandevia, 2009 ). Crucially, in order to isolate the potential effects of PD on kinaesthesia, a subject's ability to accurately detect motion (or a change in position) must be examined under Experimental Neurology 227 (2011) [26] [27] [28] [29] [30] conditions that do not require voluntary movement or visual processing of information which are also affected by PD. For example, active matching tasks have commonly been used for this purpose. With this approach, a target limb is passively placed in a particular position, and the test subject is then asked to voluntarily move the opposite limb, in an attempt to either match the end position (or mimic the movement path) of the target limb. A problem with this approach is that any errors could be attributed to deficits in either kinaesthesia or motor output of the actively moving limb (both of which are influenced by PD). Such interpretational difficulties also hamper movement recall tasks (Adamovich et al., 2001; Keijsers et al., 2005) and tasks involving vibration (Khudados et al., 1999; SmileyOyen et al., 2002; Valkovic et al., 2006) , as they rely on the integrity of both sensory and motor pathways. Likewise, any task involving visual feedback of the limb, or visual targets to which the limb should be matched (Adamovich et al., 2001; Keijsers et al., 2005) , are not suited to examine the effects of kinaesthesia alone, as they rely as much on the subject's accurate perception and integration of visual cues, as they are on kinaesthetic function.
Consequently, only those studies that have utilized passive movements of the limbs can be relied upon as measures of true kinaesthesia in PD. There are a variety of different passive movement study designs in the literature that have been used to compare kinaesthetic function between PD patients and age-matched controls. For example, PD patients and controls have been required to correctly indicate the direction of a perceived movement following passive displacement of a limb by the experimenter (Schneider et al., 1987; Maschke et al., 2003; Konczak et al., 2007; Putzki et al., 2006) . In some experiments, the time required to detect a passive limb displacement is measured (Konczak et al., 2007) . In other designs, subjects are asked to discriminate the temporal or magnitude difference between two distinct passive movements of the same joint (Putzki et al., 2006; Fiorio et al., 2007) , to estimate the relative change in a limb position (Demirci et al., 1997; Zia et al., 2002) or to discriminate relative differences in static end positions of two bilateral joints that have been displaced passively by the experimenter (Zia et al., 2000; O'Suilleabhain et al., 2001) . Under all of the above conditions, the muscles are quiescent, and vision is removed to eliminate any confounding influences of PD-related deficits in motor control or visual dependence. In all these studies, PD patients demonstrated abnormal kinaesthesia. Specifically, they consistently underestimated the amplitude of joint motion, demonstrated poorer accuracy and higher detection thresholds compared to healthy agematched controls.
There are three striking features of all studies that used passive movements to compare kinaesthetic function between PD patients and controls. The first is that all studies were restricted to movements about a single joint. The second is that all studies of passive movements in PD were restricted to joints in the upper limb, hand, or face. This is understandable, because measuring kinaesthesia along the body axis is technically much more difficult compared to assessment of the limbs or digits, which are much easier to manipulate independently and bilaterally. Moreover, measuring axial kinaesthesia is complicated by the fact that the threshold for detecting trunk position decreases when a subject is supine, compared to when the same subject is actively standing upright (Jakobs et al., 1985) . Subjects would therefore have to be tested while standing, in order to properly judge the functional implications of any axial kinaesthetic deficits in patients with PD. And the third main feature is that virtually all prior studies have been restricted to patients who were tested after normal intake of their antiparkinson medication, with the exception of one study of 17 patients who were tested in both the ON and OFF state (O'Suilleabhain et al., 2001) , and one in which subjects were tested only in the OFF state (Fiorio et al., 2007) .
Axial kinaesthesia is impaired in Parkinson's disease
The recent study by Wright and colleagues (2010) therefore represents a novel and important step forward in the study of kinaesthesia in PD. In this study, an 'axial twisting' technique used previously to examine axial hypertonicity in PD (Gurfinkel et al., 2006; Wright et al., 2007) was modified to assess axial kinaesthesia (Wright et al., 2010) . Specifically, subjects stood unaided while their axial segments were being passively twisted about the horizontal plane by a torsional rotation device, at a very low constant rotational velocity (1°/s). This type of rotation involves no imposed shifts in body mass or changes in orientation of the body relative to gravity. The outcome was quantitative, and consisted of the detection threshold and directional accuracy of the hip relative to the feet (this was termed 'Hip Kinaesthesia') and of the hip relative to the shoulders ('Trunk Kinaesthesia'). Patients were tested first in a socalled practically defined OFF state (in the morning, at least 12 h after intake of the last dose of medication), and then again during an ON state, about 45 min after intake of the usual first morning dose of Parkinson medication. In total 12 PD patients and 14 age-matched controls participated.
Results in these types of experiments are typically expressed as the ability to determine the correct direction of motion, and the threshold for detecting onset of motion. Both outcomes were abnormal in PD patients: the accuracy in determining the direction of axial twisting was reduced, while the thresholds for perception of axial twisting were increased. This was present both at the level of the hip and trunk. But the most fascinating observation was that, unexpectedly, these abnormalities were most pronounced in patients during the ON state, but much smaller during the OFF state. In other words, dopaminergic medication -which is normally used to improve the symptoms of PD, as it did in these patients -significantly worsened axial kinaesthesia. In fact, the extent to which axial kinaesthesia worsened between ON and OFF states correlated with the degree of disease severity in the OFF state. An additional, but less important, finding was that PD subjects with disease onset on the left side of their body showed significantly higher axial thresholds than subjects with right-onset PD.
As such, this study represents the first to examine kinaesthesia during axial movements. And by extension, this report is also likely the first to examine kinaesthesia involving simultaneous movements of multiple joints. A further novel aspect is that this was likely the first study to examine kinaesthesia from a joint under normal functional loading (i.e. during upright stance). Most other studies used a more artificially test environment, where the limb that was being passively moved was isolated, or supported by a manipulandum. Finally, this study is only the second to ever systematically test the effect of medication on PD-related kinaesthetic deficits, and with unexpected results.
Interpretational issues Adverse effects of medication
Although unexpected, the finding that Parkinson medication appeared to worsen kinaesthesia is actually consistent with other published work. O'Suilleabhain and colleagues (2001) used passive displacements of bilateral elbow joints to examine kinaesthesia in PD patients in the ON and OFF state, and in age-matched controls. Similar to the findings of Wright et al. (2010) , this study reported abnormal kinaesthesia in PD patients in the ON state compared to OFF state. Comparisons with controls indicated that deficits in kinaesthesia were restricted to PD patients in the ON state (Zia et al., 2002) . These observations are consistent with the majority of other studies that found abnormal kinaesthesia in PD patients tested only in the ON state (Demirci et al., 1997; Maschke et al., 2003; Konczak et al., 2007; Fiorio et al., 2007; Zia et al., 2002) .
How to interpret these findings? First, the medication effects observed by Wright and colleagues (2010) do not appear to be caused by methodological flaws, because patients were properly tested in both medication states. The OFF state was properly defined according to international standards (Langston et al., 1992) , i.e. more than 12 h after intake of the last dose of medication. It may take additional time -days or even weeks -to completely eliminate all medication effects, so formally speaking, medication effects during the OFF state as tested here cannot be excluded. However, taking patients off their medication for longer periods of time is ethically not justifiable. The ON state was defined as a subjective response to the normal medication dose, and was accompanied by an objectively documented improvement in clinical scores. Again, this is probably sufficient, although ideally subjects should have been tested after an individually tailored supramaximal medication dose, to ensure an optimal ON state, and also to avoid that patients gradually turned OFF again during the experiment (Visser et al., 2008a (Visser et al., , 2008b . But it is unlikely that such smaller medication effects can explain the findings by Wright and colleagues (2010) .
This leaves open two possible explanations: either medication had direct adverse effects on kinaesthesia, or medication affected kinaesthesia indirectly, via an effect on other symptoms of PD. Dopaminergic medication is known to have adverse motor effects, in particular in advanced disease stages where patients can suffer from response fluctuations and peak-dose dyskinesias. In fact, some have even proposed that the drug-induced dyskinesias may reflect movements generated purposefully by the CNS to compensate for abnormal kinaesthesia in the ON state (Zia et al., 2002) . There is some evidence to support direct dopaminergic medication effects on sensory afferent pathways in PD. For example, studies have shown abnormal reduction of short latency afferent inhibition on the motor cortex in PD patients in the ON compared to OFF state (Sailer et al., 2003) .
There is also the possibility that medication affects kinaesthesia indirectly, via an effect on other symptoms of PD. For example, in the case of Wright et al. (2010) , medication may have offered a partial correction of the patient's stooped posture, and this could potentially have changed the axis of rotation (and thus the line of pull for muscle stretch and joint loading). It is possible that the stretched muscles in stooped patients were more sensitive to axial torsion, providing greater afferent feedback in the OFF condition. Similarly, medication may have reduced axial muscle rigidity in PD patients. In the OFF state when patients were more rigid, the externally applied axial rotation may have required greater force, inducing greater pull on e.g. the skin. This in turn could have provided patients with additional afferent feedback, explaining why kinaesthesia falsely appeared to be better in the OFF state. Indeed, it is likely that the experimental design used by Wright and colleagues also evoked cutaneous feedback, as pulling on the straps will likely provide cutaneous cues to the direction of the pull, which can generate strong kinaesthetic sensations (Proske and Gandevia, 2009 ).
Possible influence on clinical manifestations
Do these findings by Wright and colleagues have any clinical relevance? The authors have demonstrated strong associations between ON-OFF differences in kinaesthetic thresholds for passive axial movements and functional impairments observed during the OFF state. The results, while interesting, are not unexpected if one considers that disease severity in the OFF state should be highly correlated to ON-OFF changes in most PD symptoms, since patients with the greatest functional impairments in the OFF state are likely have the highest capacity for improvements from medication. Therefore greater clinical insight could be gained in the future by investigating the association between ON-OFF kinaesthetic differences in relation to ON-OFF changes in axial, PIGD and motor symptoms, in order to determine which PD deficits, including dyskinesias (Zia et al., 2002) , may be linked to medication-induced changes in kinaesthesia.
Furthermore, the present experiment did not test axial kinaesthesia and dynamic balance control in the same subjects, which is needed when searching for a direct relationship. The same applies to a possible correlation with falls in daily life. This should now be tested in follow-up experiments. These should also test kinaesthesia in the legs, and also examine hip or trunk kinaesthesia for other movement directions that are associated with the greatest postural instability in PD, in particular in the backward direction (Carpenter et al., 2004; Dimitrova et al., 2004) . In the next paragraphs, we will discuss a few possible implications of the findings by Wright and colleagues.
Automatic postural reactions
Based on the available evidence, it actually seems unlikely that axial kinaesthetic deficits contribute to the abnormalities in automatic postural reactions observed previously in PD. Certainly, proprioception is an important contributor to normal postural reactions elicited by unexpected externally imposed perturbations. For example, patients with distal sensory neuropathies have decreased amplitudes of triggered postural responses (Bloem et al., 2000; Jauregui-Renaud et al., 1998) , while patients with proprioceptive loss of the proximal joints additionally have markedly delayed postural reactions (Bloem et al., 2002) . If balance impairment in PD patients would be related to a global loss in proprioception, then their postural responses would be expected to be attenuated, and potentially delayed if proximal deficits are involved. However, PD patients have normal timing of postural reactions, and in fact show excessive muscle activity in their automatic balance reactions (Carpenter et al., 2004; Folkerts and Njiokiktjien, 1972; Schieppati and Nardone, 1991; Scholz et al., 1987) . Furthermore, unlike kinaesthetic abnormalities, which appear to be worsened by dopaminergic medication (Wright et al., 2010; O'Suilleabhain et al., 2001) , postural reactions are typically not responsive to dopaminergic medications (Carpenter et al., 2004; Bloem et al., 1996) . Similarly, deep brain stimulation can improve kinaesthesia in PD (Maschke et al., 2005) , but provides a less convincing improvement in postural reactions of PD patients (Visser et al., 2008a; Maurer et al., 2003) . Therefore, deficits in the timing and modulation of postural reactions in PD are unlikely to be caused by abnormalities in kinaesthesia. However, abnormal processing of proprioceptive feedback could affect the ability of patients to properly adjust the gain of their postural responses to changing characteristics of balance perturbations. This could explain the fixed gain of postural responses that underlies postural inflexibility in PD (Bloem et al., 1995; Horak et al., 1992) .
Stooped posture
Deficits in axial kinaesthesia could lead to abnormal posturing. For example, in situations where the support surface is shifted from a purely horizontal position, PD patients have difficulty re-orient themselves to a vertical position without the aid of visual cues (Vaugoyeau et al., 2007; Proctor et al., 1964) . Because of their defective axial kinaesthesia, patients might also falsely perceive their subjective vertical to be shifted backward, forcing them to adopt a stooped posture (Kitamura et al., 1993) . Some evidence supports this concept of incorrect trunk perception. In one experiment, patients were confronted with line drawings showing varying degrees of stoop and lateral deviation (Moore et al., 2000) . When asked to identify the drawing that best resembled their self-perceived posture, patients were likely to underestimate the severity of their abnormalities. This suggests that patients have lost their normal sense of trunk position in space. This finding supplements clinical experience that many patients are surprised to observe their own posture in a mirror.
Axial versus appendicular disability
Could deficits in kinaesthesia explain previous observations that suggested a differential therapeutic response of axial motor control versus appendicular motor control (upper limb movements)? Indeed, other investigators have reported a disconcordant therapeutic effect on appendicular versus axial motor, in terms of both the beneficial treatment response and the adverse effects. We will discuss two examples of a differential therapeutic response. The first is a study that examined the effect of STN stimulation on both appendicular movements (reaching with the arms) and axial motor control (walking) (Bastian et al., 2003) . Unilateral stimulation improved reaching, but not walking, for which bilateral stimulation was required. The investigators suggested that the basal ganglia pathways involved in control of walking and reaching may be distinct, and this could perhaps also explain the differences in medication effects. The second is a study from our lab, where we examined PD patients placed on a multidirectionally moving support surface (Visser et al., 2008a) . The results showed that the protective arm movements responded better to dopaminergic treatment than axial trunk control.
The adverse effects of treatment can also differ for axial and appendicular motor control. For example, in a follow-up study of patients with bilaterally implanted STN stimulators, we found that many patients experienced a worsening of gait, despite a persistent beneficial effect on appendicular movements (van Nuenen et al., 2008) . Certainly, such findings would suggest that arm and trunk movements may be served by dissociable neurophysiologic circuits and dopaminergic pathways. It would be logical to then speculate that dopaminergic medication could specifically impair axial kinaesthesia, in the face of concurrent beneficial effects on limb control. However, this seems unlikely, because kinaesthesia has also been found to be defective in the arms of PD patients (Schneider et al., 1987; Zia et al., 2000; Maschke et al., 2003; Konczak et al., 2007; Putzki et al., 2006; Fiorio et al., 2007; O'Suilleabhain et al., 2001) . Moreover, as pointed out earlier, deficits in limb kinaesthesia also predominate in the ON state (O'Suilleabhain et al., 2001) , similar to the findings of Wright et al. (2010) for the trunk, so kinaesthesia seems equally impaired for axial and appendicular movements.
Turning
It is obvious to speculate on the possibility that the rotational kinaesthetic deficits observed by Wright and colleagues may explain the difficulties of PD patients in making yaw rotations (i.e. about their longitudinal axis). This is clinically evident in early stages of the disease, when patients experience difficulties turning around in bed (Lakke, 1985) . Patients also have difficulties turning while seated (Bridgewater and Sharpe, 1998) , and particularly when they try to turn around in the standing position, even when straight walking is still normal (Crenna et al., 2007) . These turning movements while standing are performed slowly (Visser and Voermans, 2007) , with small and abnormally timed steps (Huxham et al., 2008; Stack et al., 2004) and 'en bloc' (i.e. without the normal multi-segmented axial flexibility) (Crenna et al., 2007; Vaugoyeau et al., 2006) . Interestingly, passively rotating PD patients in the yaw plane with their entire body (by placing them on a rotating disk) is not abnormal (Earhart et al., 2007) , underscoring the importance of kinaesthetic deficits occurring at the level of the hips or trunks, as demonstrated by Wright and colleagues.
The great relevance of these findings lies within the relation to falls and injuries. Turning around the body's axis is the most important cause for freezing of gait in PD (Schaafsma et al., 2003; Snijders et al., 2008) . In turn, freezing of gait is an important risk factor for falls in PD (Latt et al., 2009; Kerr et al., 2010) . Falls occurring while turning cause the subject to fall sideways, and this is commonly associated with hip fractures (Greenspan et al., 1998) . And these hip fractures are associated with considerable morbidity and even an increased mortality in patients with PD, and are a leading reason for nursing home admission (Idjadi et al., 2005; Coughlin and Templeton, 1980; Eventon et al., 1983) . So any therapeutic interventions that would improve axial kinaesthesia could potentially have great benefit for patients with PD. In the next paragraph, we will briefly discuss several therapeutic possibilities.
Consequences for treatment
It is too early to even speculate whether the findings of Wright and colleagues should be a reason for concern about the use of dopaminergic medication in PD. Cause or consequence could not be differentiated in this study. While all patients used levodopa, 10 patients additionally used a dopamine receptor agonist, and a few patients also used an anti-cholinergic, amantadine or selegiline. Therefore, it is impossible to pinpoint one class of drugs as being potentially responsible for the observed changes in kinaesthesia in ON compared to OFF states. Moreover, convincing as the laboratory finding may have been, the Wright study did not directly link the observed rotational kinaesthetic deficits to clinically relevant symptoms, such as the ability to turn while walking, or the risk of falling. Obviously, such studies should now be high on the research agenda. Until new findings arrive, it is safe to state that the many great benefits of dopaminergic medication outweigh any theoretical risks about adverse effects on axial kinaesthesia.
It also needs to be acknowledged that the reduced kinaesthesia in the ON state may actually be considered beneficial by the patients. Perhaps untreated PD is characterised by a somatosensory integration deficit: kinaesthetic signals are being processed incorrectly due to basal ganglia dysfunction (mainly within the globus pallidus), leading to an abnormal body scheme (Filion et al., 1988) . Sometimes it is better to have no afferent feedback, instead of a flawed feedback signal. This scenario would predict that medication suppresses the abnormal trunk signals, allowing patients to rely on other and more reliable sources of feedback, such as vestibular signals which appear to be processed normally -or even in an exaggerated way -in patients with PD (Pastor et al., 1993) .
Could stereotactic deep brain surgery (DBS) provide an alternative to medication? It is widely appreciated that the clinical effects of DBS mimic those of dopaminergic medication, so any concerns about drugs should also apply to surgery. However, one study reported that DBS partially improved limb kinaesthesia (Maschke et al., 2005) , while another study found that DBS could restore medication-induced reductions of short latency afferent inhibition (Sailer et al., 2007) . More work is needed here, focusing on axial kinaesthesia in larger patient groups, and also comparing different surgical targets.
Finally, physiotherapy can be considered as a possible treatment to correct or compensate for axial kinaesthetic deficits. In the field of orthopaedics, randomised clinical trials have demonstrated beneficial effects of proprioceptive training (Lin et al., 2009; Liu-Ambrose et al., 2003) . However, the recently updated evidence-based guideline of physiotherapy for PD does not include proprioceptive training as part of the therapeutic arsenal that is supported by evidence or clinical experience (Keus et al., 2009 ). Clearly, this now needs to be taken to the test in properly designed studies.
Conclusion
The study by Wright and colleagues is important, as it draws attention to the presence and possible importance of axial kinaesthetic deficits for various clinically relevant symptoms in PD. The results underscore that postural problems in PD can -at least to some extent -be regarded as a proprioceptive disorder, next to the wellknown role played by motor deficits. As any good study does, the results of the Wright study also raised more questions than it provided answers, offering an exciting menu of new research studies. Taken together, this creates new hopes for patients and clinicians of finding innovative solutions to treat this incapacitating disease.
